Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics
Abstract
Nine patients receiving a low dose (25 mg) and ten receiving a standard dose (150 mg) of depot haloperidol every four weeks were assessed every three months for two years. Patients also received targeted oral neuroleptics as needed. No significant between-group differences were found in clinical outcome as measured by number of hospital admissions, days hospitalized, scores on the Brief Psychiatric Rating Scale and the Global Assessment Scale, and level of extrapyramidal symptoms. Combining low-dose depot and targeted oral neuroleptics was at least as effective as using a standard depot dose and for many patients may provide the best way to reach the minimal effective dose for maintenance treatment.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).